Analysis Of Income And Expense [Abstract]

Mithra Pharmaceuticals S.A. - Filing #3183075

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
66,997,000 EUR
22,668,000 EUR
Material income and expense [abstract]
Research and development expense
64 041 EUR
85 243 EUR
Selling, general and administrative expense [abstract]
Selling expense
2 100 EUR
1 871 EUR
General and administrative expense
14 675 EUR
12 515 EUR
Income tax relating to components of other comprehensive income [abstract]
Income tax relating to components of other comprehensive income that will be reclassified to profit or loss
2 612 EUR
3 597 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
- EUR
18 298 EUR
77 918 EUR
59 620 EUR
- EUR
17 300 EUR
- EUR
- EUR
134 175 EUR
116 875 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
77 918 EUR
134 175 EUR
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
- EUR
- EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.